Evidence map›Paper›PMID 41890029›Full record

ArticlebioRxiv : the preprint server for biology2026

Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma.

Nilgun Tasdemir, Laura Savariau, Julie Scott, Joseph D Latoche, Kyle Biery, Zheqi Li, Emily A Bossart, Sreeja Sreekumar, Daniel D Brown, Sarah Wang and 14 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Nilgun TasdemirWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Laura SavariauWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Julie ScottWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Joseph D LatocheUPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Kyle BieryWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Zheqi LiWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.ORCID 0000-0003-1213-640X
Emily A BossartWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Sreeja SreekumarWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Daniel D BrownInstitute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, PA 15213, USA.
Sarah WangDepartment of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Rebecca J WattersWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Azadeh NasrazadaniWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Ye QinWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Ye CaoWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Fangyuan ChenWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
George TsengDepartment of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0002-5447-1014
Carlos CastroMagee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Carolyn J AndersonDepartment of Medicine, Cardiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 USA.
Jennifer AtkinsonWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
Jagmohan HoodaWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.ORCID 0000-0001-5001-6092
Peter C LucasDepartment of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Nancy E DavidsonDepartmen of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Adrian V LeeWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.ORCID 0000-0001-9917-514X
Steffi OesterreichWomens Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee Womens Research Institute, Pittsburgh, PA 15213, USA.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Developing and credentialing murine models of ILCR01CA252378 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Adrian V Lee, Steffi Oesterreich · 2021 to 2026
$3.0M
High-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574k
Non-canonical FADD signaling as a genetic driver of invasive lobular carcinomaK99CA237736 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TASDEMIR, NILGUN · 2019 to 2020
$256k
Targeting the EMT-like Phenotype in Invasive Lobular CarcinomaF31CA203055 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOSSART, EMILY ANN · 2016 to 2017
$84k
NCI NIH HHS F31 CA203055NCI NIH HHS K99 CA237736NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA252378NIH HHS S10 OD028483
6 · The paper itself

Abstract

Invasive lobular breast carcinoma (ILC), the most common special histological subtype of breast cancer, is characterized by nearly universal expression of estrogen receptor alpha (ER) and unique sites of metastases, neither of which is fully recapitulated by genetically engineered mouse models. Using reporter-labeled ILC mouse xenografts, herein we used mammary fat pad, tail vein and intracardiac orthotopic growth to analyze spontaneous and experimental metastasis and gene expression. We observed ER-positive primary tumors with single-file histology and collagen deposition, and spontaneous metastasis from the mammary fat pad to bones, ovaries, and brain including the leptomeninges, thereby closely mirroring the growth and metastatic spread of human ILC. Brain metastases showed strong ER staining, confirmed by sequencing analyses which identified estrogen signaling as top activated pathway, and the lesions exhibited robust response to endocrine therapy. In summary, we report endocrine responsive mammary fat pad, tail vein and intracardiac xenografts that faithfully demonstrate unique ILC features and can serve as invaluable pre-clinical translational platforms for validating candidate ILC genetic drivers and testing novel therapeutics.

Indexed as

bioluminescent imagingendocrine responseER alphaILCintracardiacinvasive lobular carcinomametastasisorthotopictail veinxenograft

Identifiers

PMID41890029
PMCPMC13015567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.